The Discovery Rule — When Did Your Clock Start?
In pharmaceutical mass tort cases, the statute of limitations typically does not begin running at the moment of injury (the child's birth or diagnosis) — it begins when the claimant knew or reasonably should have known of the connection between the product and the injury. This is called the discovery rule. For Tylenol autism claimants, the relevant question is: when did you (or when should you have) first known that prenatal acetaminophen use could cause ASD or ADHD? Because the Nature Reviews Endocrinology consensus statement and major media coverage of the lawsuit did not occur until 2021, and the MDL was not formed until late 2022, many families had no reasonable basis to make this connection before 2021 or 2022. Under discovery-rule arguments, limitations periods for many families may have begun in 2021 or 2022 — giving 2-year-SOL states until 2023 or 2024, and 3-year-SOL states until 2024 or 2025. Families whose discovery period began later may still be within their window in 2026. An attorney must evaluate your specific state and circumstances.
Minority Tolling — Why Your Child's Age Matters
Most states have minority tolling provisions — the statute of limitations for a child's personal injury claim does not begin running until the child reaches the age of 18 (majority). This means that for a child diagnosed with ASD or ADHD in 2015, the statute of limitations may not expire until 2033 (18 years after birth, assuming a 2015 birth) in states with minority tolling. California, Illinois, New York, and most other states have some form of minority tolling, though the specifics vary. This is one of the most important deadline considerations for Tylenol autism claims and may protect many families who believe their window has already closed. Do not assume your deadline has passed without consulting an attorney.
Frequently Asked Questions
Related Pages
Tylenol Liver Damage Lawsuit
Acetaminophen — the active ingredient in Tylenol — is the leading cause of acute liver failure in the United States, responsible for approximately 56,000 emergency room visits, 26,000 hospitalizations, and nearly 500 deaths each year. Lawsuits allege that McNeil Consumer Healthcare and parent company Johnson & Johnson failed to adequately warn consumers about the narrow margin between a therapeutic dose and a potentially fatal overdose. Even doses only slightly above the recommended amount, especially when combined with alcohol use or taken across multiple acetaminophen-containing products, can cause catastrophic liver damage. If you or a loved one suffered acute liver failure, liver transplant, or death linked to acetaminophen use, you may be eligible for compensation. These liver damage claims are separate from the Tylenol autism/ADHD litigation — they involve direct injury to the person who took the medication.
Learn moreLearn moreLearn moreLearn moreLearn moreLearn moreTylenol Autism Lawsuit Lawsuit
Acetaminophen — sold under the brand name Tylenol by Kenvue (formerly Johnson & Johnson) and as dozens of store-brand generics by Walmart, CVS, Walgreens, Target, Costco, Meijer, and others — was the most commonly used pain reliever during pregnancy in the United States for decades. Starting with a landmark 2018 American Journal of Epidemiology meta-analysis of 130,000 mother-child pairs, and culminating in a 2021 consensus statement signed by 91 scientists published in Nature Reviews Endocrinology, accumulating evidence linked prolonged prenatal acetaminophen exposure to significantly elevated risks of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The federal multidistrict litigation, MDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation) in the Southern District of New York, was dismissed in August 2024 after Judge Denise L. Cote excluded all plaintiffs' general causation experts under the Daubert standard. Critically, the Second Circuit Court of Appeals heard oral arguments on November 17, 2025 — and two of the three judges on the panel openly questioned whether Judge Cote acted too aggressively in excluding the expert testimony. A reversal by the Second Circuit could reinstate thousands of federal cases. Separately, California state courts (Alameda County) and Illinois state courts (St. Clair, Madison, and Cook counties) have active acetaminophen-autism cases proceeding under the Frye admissibility standard, which does not apply the same gatekeeping test that closed the federal MDL. Store-brand acetaminophen users have the same legal claims as Tylenol brand users — the failure-to-warn theory applies equally to Walmart's Equate brand, CVS Health brand, Walgreens brand, Costco Kirkland brand, and all other private-label acetaminophen products.
View full case overview